Stock Ratings / Health Care / MNKD / dividends

HROW (71) SPTX (56) CTY (61) AVLN (49) ⌘ Pro Terminal →

MannKind Corporation (MNKD) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.50 +2.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

MannKind Corporation (MNKD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±11.1%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $33,350

Est. Year-10 Shareholder Yield: $200/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.7K

Yr 2

$14.4K

Yr 3

$16.2K

Yr 4

$18.3K

Yr 5

$20.6K

Yr 6

$23.2K

Yr 7

$26.2K

Yr 8

$29.6K

Yr 9

$33.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in MNKD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on MNKD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.67%▼ DESCENDING CHANNEL

2026-10-30O $3.50H $3.57L $3.45C $3.50VOL 2.01M

RES: $4.21SUP: $2.73SMA50: $3.58SMA200: $3.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNKD Butterfly Map → + Track MNKD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)

Health Care Rank #158 of 1016 ⚔️ HROW vs MNKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNKD vs. HROW, SPTX, CTY, AVLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #158 by composite RQD confidence (63/100, grade C) and #348 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, MNKD leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with MNKD at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MNKD ACTIVE MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	Benchmark Subject
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-mnkd →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-mnkd →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-mnkd →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-mnkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$349.0M	$5.9M	$18.3M	$13.7M	$792.2M	—
FY2024 (FY)	2024-12-31	$285.5M	$27.6M	$42.5M	$32.8M	$393.8M	—
FY2023 (FY)	2023-12-31	$199.0M	-$11.9M	$34.1M	$34.1M	—	—

3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MannKind Corporation (NASDAQ: MNKD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $3.50 (+2.04% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #158 in composite RQD confidence.

How does MNKD compare to HROW and SPTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, HROW (Harrow Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B) and SPTX (Seaport Therapeutics Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, MNKD leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNKD?

Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?

MNKD last traded at $3.50 (+2.04% on volume of 2,276,272 shares), positioning the stock -2.23% below its 50-day simple moving average ($3.58) and -6.17% below its 200-day simple moving average ($3.73). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 29.7% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.1% ($3.11 to $3.89).

MNKD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does MNKD pay a dividend and is it safe?

MannKind Corporation (MNKD) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: MNKD RQD Cockpit MNKD 12M Forecast MNKD Earnings & Move MNKD Dividends & DRIP MNKD Insiders & 13F MNKD Whale Options MNKD Profit Sankey MNKD News & Why